endocrinology
Bone health

Romosozumab included in new guideline recommendations for severe osteoporosis

The bone anabolic agent romosozumab is now recommended as first line treatment for postmenopausal women with severe osteoporosis in an update to Endocrine Society guidelines. The drug “should be considered as a first-line therapy in patients with multiple vertebral fractures or hip fracture and BMD in the osteoporotic range,” according to the update published in ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic